Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
Kevin R. Kelly(Keck Hospital of USC), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center)
Cited by 78
Related Papers
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
|Nature Medicine|2023|226
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
|Blood Advances|2020|224
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
|Blood|2021|213
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
|Blood Advances|2021|146